Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 10/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGAV | P06756 | 2/20 | 0.57 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | DDX3X | O00571 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 9/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150239 | 0.90 | NR1H4 (0.55) | ITGB1NR1H4DDX3XITGA4KMT2A | |
| SCHEMBL5151666 | 0.89 | RAB9A (0.61) | ITGB1ITGB3ITGAVITGA5NR1H4 | |
| SCHEMBL5153169 | 0.89 | MEN1 (0.52) | ITGB1ITGB3ITGAVITGA5NR1H4 | |
| SCHEMBL5153450 | 0.89 | NR1H4 (0.52) | ITGB1ITGB3ITGAVITGA5NR1H4 | |
| SCHEMBL5156956 | 0.89 | ITGB1 (0.52) | ITGB1ITGB3ITGAVITGA5DDX3X | |
| SCHEMBL5156432 | 0.89 | ITGB1 (0.52) | ITGB1ITGB3ITGAVITGA5NR1H4 | |
| SCHEMBL5700960 | 0.87 | MEN1 (0.51) | ITGB1ITGB3ITGAVITGA5NR1H4 | |
| SCHEMBL4683165 | 0.87 | ITGA4 (0.67) | ITGB1ITGB3ITGAVITGA5ITGA4 | |
| SCHEMBL5157330 | 0.87 | MAPT (0.56) | ITGB1HPGDITGA4KMT2AKDM4E | |
| SCHEMBL5700810 | 0.87 | ITGB1 (0.50) | ITGB1ITGB3ITGAVITGA5NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1027328-B1 | SUBSTITUTED ANILIDES | AVENTIS PHARMA LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| EP-1189612-A4 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6479519-B1 | INHIBITORS OF CELL ADHESION; TREATMENT OF ASTHMA OR INFLAMMATORY BOWEL DISEASE | AVENTIS PHARMA LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1189612-A1 | VLA-4 INHIBITOR COMPOUNDS | Daiichi Pharmaceutical Co., Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| EP-1027328-A1 | SUBSTITUTED ANILIDES | Aventis Pharma Limited (GB) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999023063-A1 | SUBSTITUTED ANILIDES | AVENTIS PHARMA LIMITED (GB) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | ITGB1 7/4885ITGB3 17/4885ITGAV 12/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ITGB1 8/4885ITGB3 18/4885ITGAV 14/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | ITGB1 7/4885ITGB3 19/4885ITGAV 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.